Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project.
DAA
HCV
Telepass
case finding
linkage to care
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
21
06
2020
revised:
15
09
2020
accepted:
20
11
2020
pubmed:
10
1
2021
medline:
1
9
2021
entrez:
9
1
2021
Statut:
ppublish
Résumé
Italy is one of the countries on track with the WHO's agenda to eliminate hepatitis C virus (HCV) by 2030. Healthcare facilities play a crucial role in seeking patients who are infected but have not yet been treated. We assessed the effectiveness of a recall strategy, named 'Telepass' project, for patients exposed to HCV infection who have not yet been linked to care in a large tertiary care centre. The 'Telepass' project was structured in two phases: (a) a retrospective analysis first identified all anti-HCV-positive subjects among patients who underwent pre-operative assessment in the facility in the course of one year; (b) a following prospective phase, aimed to recall patients in need either of further diagnostic tests (ie HCV-RNA) or treatment. A total of 12246 records of patients tested for HCV antibodies were reviewed. The overall prevalence of anti-HCV-positive subjects was 1.83% (224/12246) with a male/female ratio of 2.07. Out of the 224 anti-HCV-positive patients, 123 (54.91%) did not have documented HCV-RNA tests and were therefore selected for recall. Of these, 123 were reachable and 26 (21.13%) were successfully linked to care. Ten patients (38.46%) tested HCV-RNA positive and initiated treatment with direct-acting antivirals (DAAs). The Telepass study highlights that a recall strategy starting from internal hospital databases can help identify patients with chronic HCV infection who have not yet been linked to care, and provides an epidemiological insight into the prevalence of HCV infection in Italy in the late DAAs era.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
651-656Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Polaris Observatory HCV. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-176.
Naggie S, Muir AJ. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs. Annu Rev Med. 2017;68:345-358.
Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology. 2017;69:487-497.
Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018;68:449-461.
Ponziani FR, Mangiola F, Binda C, et al. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol. 2017;9:352-367.
Arias A, Aguilera A, Soriano V, et al. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir Ther. 2017;22:307-312.
Tang L, Parker A, Flores Y, et al. Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population. J Viral Hepat. 2018;25:205-208.
Tapper EB, Bacon BR, Curry MP, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017;24:22-27.
World Health Organization. Global health sector strategy on viral hepatitis, 2016-2021. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=C63125F3E486BB280C53564C414F5130?sequence=1
https://apps.who.int/iris/bitstream/handle/10665/310912/9789241515191-eng.pdf?ua=1. Accessed on June 2020.
European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC; 2016.
Stroffolini T, Menchinelli M, Taliani G, et al. High prevalence of hepatitis C virus infection in a small central Italian town: lack of evidence of parenteral exposure. Ital J Gastroenterol. 1995;27:235-238.
Maio G, D’Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J Hepatol. 2000;33:116-120.
Di Stefano R, Stroffolini T, Ferraro D, et al. Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. J Med Virol. 2002;67:339-344.
Cozzolongo R, Osella AR, Elba S, et al; NUTRIHEP Collaborating Group. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol. 2009;104:2740-2746.
https://apps.who.int/iris/bitstream/handle/10665/204501/9789241549547_eng.pdf?sequence=1. Accessed on June 2020.
Datta S, Horwood J, Hickman M, Sharp D. Case-finding for hepatitis C in primary care: a mixed-methods service evaluation. Br J Gen Pract. 2014;64:e67-74.
Calner P, Sperring H, Ruiz-Mercado G, et al. HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center. PLoS One. 2019;14:e0218388.
Kracht PAM, Arends JE, van Erpecum KJ, et al. REtrieval And cure of Chronic Hepatitis C (REACH): Results of micro-elimination in the Utrecht province. Liver Int. 2019;39:455-462.
Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors and genotype distribution of hepatitis C virus infection in the general population: a community based survey in Southern Italy. Hepatology. 1997;26:106-111.
Marascio N, Liberto M, Barreca G, et al. Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infect Dis. 2014;14:S2.
Guadagnino V, Stroffolini T, Caroleo B, et al; Sersale's Study Group. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection. Dig Liver Dis. 2013;45:403-407.
Andriulli A, Stroffolini T, Valvano MR, et al. Declining prevalence and increasing awareness of hepatitis C virus infection in Italy: a population-based survey. Eur J Intern Med. 2018;53:79-84.
Sagnelli E, Stroffolini T, Mele A, Almasio P. The importance of HCV on the burden of chronic liver disease in Italy: a multicentre study. J Med Virol. 2005;75:522-527.
The Writing Committee on behalf of the Consensus Panel. Expert Consensus Conference: the screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005. Dig Liver Dis. 2006;38:445-451.
Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis. 2009;41:689-699.
Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of southern Italy. J Hepatol. 1997;27:30-35.
Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109-120.
Perz JF, Grytdal S, Beck S, et al. Case-control study of hepatitis B and hepatitis C in older adults: Do healthcare exposures contribute to burden of new infections? Hepatology. 2013;57(3):917-924.
Agenzia Italiana del Farmaco. www.aifa.gov.it. Accessed October 21, 2019.
Kondili LA, Gamkrelidze I, Blach S, et al. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver Int. 2020;40(7):1545-1555.
Sagnelli E, Alessio L, Sagnelli C, et al. Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and low-income refugees in three areas of Southern Italy. Ann Hepatol. 2018;17:47-53.
Galli M, Ridolfo A, van denBogaart L, Negri C, Giacomelli A. HCV and immigration in Italy. Acta Biomed. 2018;89:19-32.